A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

April 8, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

BIIB133 (Dapirolizumab pegol)

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm

Trial Locations (1)

Anaheim Clinical Trials, Anaheim